Company news
Tenax Therapeutics, Inc. news in 2025
Tenax Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
December 17, 2025
Tenax Therapeutics Announces Result of Prespecified Blinded Sample Size Assessment
December 16, 2025
Tenax Therapeutics to Participate in Upcoming Investor Conferences
November 25, 2025
Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2025
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF
November 6, 2025
Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
November 3, 2025
Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
September 16, 2025
Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
August 28, 2025
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 13, 2025
Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 25, 2025
Tenax Therapeutics Announces $25 Million Private Placement
March 5, 2025
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
March 5, 2025
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference
March 3, 2025
Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations
January 21, 2025